Insulet Corp. Stock Hits New 52-Week Low at USD 215.26

Insulet Corp., a mid-cap player in the Pharmaceuticals & Biotechnology sector, has reached a new 52-week low of USD 215.26 as of March 25, 2026. This decline marks a significant downturn for the company, which has seen its stock price drop considerably from its 52-week high of USD 354.88. Despite a one-year performance of 12.48%, Insulet's returns have lagged behind the S&P 500's 13.68%. The company has demonstrated healthy long-term growth, with net sales increasing at an annual rate of 24.53% and operating profit rising by 55.87%. However, the stock's performance has been impacted by a return on capital employed (ROCE) of 11.86%, indicating challenges in management efficiency and profitability. Insulet's market capitalization stands at USD 15,815 million, with a price-to-earnings ratio of 46.00. The company maintains a low debt-equity ratio of 0.16, reflecting a conservative approach to leverage. Despite high institutional holdings at 100%, which suggests strong confidence from large investors, the stock has faced below-par performance in both the near and long term, generating a return of -17.71% over the past year.